Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aurobindo Pharma, an India-based Pharma company, is mulling to enter into an agreement with Pfizer to supply bulk drugs for generics market in Japan and Korea.
Subscribe to our email newsletter
The Hyderabad-based Aurobindo Pharma is expected to sign an agreement regarding this with Pfizer, reported The Financial Express.
Currently, Aurobindo is in pact with Pfizer for the marketing of approximately 100 products in US, Europe and other markets.
The Financial Express has quoted Aurobindo Pharma chairman PV Ramprasad Reddy as saying that they will soon be exploring the Japanese and Korean markets through an agreement with Pfizer for supply of bulk drugs.
"The company proposes to manufacture about 30 active pharmaceutical ingredients (APIs) to Pfizer, which in turn, will take care of packaging and branding. Pfizer already has three formulation units in Japan," Reddy said.
"We would specially renovate one of our plant in AP at an investment of $8m, which would adhere to all the regulatory norms of the Japanese government norms and Pfizer would take care of the renovation expenses."